Strata Oncology Receives Medicare Coverage for NGS Test

Strata Oncology announced Tuesday its StrataNGS comprehensive genomic profiling test is covered under a local coverage determination from Medicare Administrative Contractor Palmetto GBA. 

The test is covered for patients with advanced stages, recurrent, relapsed, refractory, and/or metastatic solid tumors under Palmetto’s general LCD for next-generation sequencing for solid tumors. The LCD is specific for solid tumor testing and “is exclusive of hematologic malignancies, circulating tumor DNA testing … and other cancer-related uses of NGS, such as germline testing” for patients with cancer, according to the LCD. The patient cannot have been previously tested by the same test for the same genetic content. 

The LCD aligns Palmetto’s coverage with a national coverage determination from the US Centers for Medicare and Medicaid Services covering NGS tests in patients with cancer.

Source: https://www.genomeweb.com/reimbursement-news/strata-oncology-receives-medicare-coverage-ngs-test